Evofem Biosciences, Inc. (EVFM): Net Income
$391.0K
Year ended 2025-12-31
-$15.28M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $391.0K | n/m | 2026-03-11, From 2025-01-01 |
| 2024-12-31 | -$8.86M | n/m | 2026-03-11, From 2024-01-01 |
| 2023-12-31 | $52.98M | n/m | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | -$76.70M | n/m | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | -$205.19M | n/m | 2023-04-27, From 2021-01-01 |
| 2020-12-31 | -$142.31M | n/m | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | -$80.03M | n/m | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | -$125.71M | n/m | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | -$105.31M | n/m | 2019-03-01, From 2017-01-01 |
| 2016-12-31 | -$13.02M | n/m | 2018-02-26, From 2016-01-01 |
| 2015-12-31 | -$43.16M | n/m | 2018-02-26, From 2015-01-01 |
| 2014-12-31 | -$10.82M | n/m | 2017-03-23, From 2014-01-01 |
| 2013-12-31 | -$15.02M | n/a | 2016-03-29, From 2013-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $391.0K | n/m |
| Scynexis Inc (SCYX) | 2025-12-31 | -$8.61M | n/m |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | -$48.06M | n/m |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | -$6.13M | n/m |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | -$203.82M | n/m |
| Alumis Inc. (ALMS) | 2025-12-31 | -$243.32M | n/m |
| uniQure N.V. (QURE) | 2025-12-31 | -$198.97M | n/m |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | -$143.75M | n/m |
| Celularity Inc (CELU) | 2025-12-31 | -$91.72M | n/m |
Compare EVFM, SCYX, CASIF, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗